Logo image of ANIP

ANI PHARMACEUTICALS INC (ANIP) Stock Fundamental Analysis

NASDAQ:ANIP - US00182C1036 - Common Stock

92.12 USD
+0.23 (+0.25%)
Last: 8/27/2025, 2:07:19 PM
Fundamental Rating

5

Overall ANIP gets a fundamental rating of 5 out of 10. We evaluated ANIP against 193 industry peers in the Pharmaceuticals industry. ANIP has an average financial health and profitability rating. ANIP has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination!


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

ANIP had positive earnings in the past year.
ANIP had a positive operating cash flow in the past year.
ANIP had negative earnings in 4 of the past 5 years.
ANIP had a positive operating cash flow in 4 of the past 5 years.
ANIP Yearly Net Income VS EBIT VS OCF VS FCFANIP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

1.2 Ratios

ANIP's Return On Assets of -1.06% is fine compared to the rest of the industry. ANIP outperforms 78.24% of its industry peers.
ANIP's Return On Equity of -3.08% is fine compared to the rest of the industry. ANIP outperforms 79.27% of its industry peers.
With a decent Return On Invested Capital value of 1.63%, ANIP is doing good in the industry, outperforming 78.76% of the companies in the same industry.
Industry RankSector Rank
ROA -1.06%
ROE -3.08%
ROIC 1.63%
ROA(3y)-2.12%
ROA(5y)-3.36%
ROE(3y)-5.31%
ROE(5y)-7.87%
ROIC(3y)N/A
ROIC(5y)N/A
ANIP Yearly ROA, ROE, ROICANIP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 -5 10 -10

1.3 Margins

Looking at the Operating Margin, with a value of 3.05%, ANIP is in the better half of the industry, outperforming 78.76% of the companies in the same industry.
ANIP's Operating Margin has declined in the last couple of years.
The Gross Margin of ANIP (61.06%) is better than 68.91% of its industry peers.
ANIP's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 3.05%
PM (TTM) N/A
GM 61.06%
OM growth 3YN/A
OM growth 5Y-47.18%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.51%
GM growth 5Y-3.12%
ANIP Yearly Profit, Operating, Gross MarginsANIP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

More info and screens

4

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ANIP is destroying value.
ANIP has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ANIP has been increased compared to 5 years ago.
The debt/assets ratio for ANIP is higher compared to a year ago.
ANIP Yearly Shares OutstandingANIP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
ANIP Yearly Total Debt VS Total AssetsANIP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

An Altman-Z score of 2.22 indicates that ANIP is not a great score, but indicates only limited risk for bankruptcy at the moment.
ANIP's Altman-Z score of 2.22 is fine compared to the rest of the industry. ANIP outperforms 66.84% of its industry peers.
ANIP has a debt to FCF ratio of 4.95. This is a neutral value as ANIP would need 4.95 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 4.95, ANIP belongs to the top of the industry, outperforming 83.42% of the companies in the same industry.
ANIP has a Debt/Equity ratio of 1.32. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 1.32, ANIP is not doing good in the industry: 75.65% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.32
Debt/FCF 4.95
Altman-Z 2.22
ROIC/WACC0.17
WACC9.76%
ANIP Yearly LT Debt VS Equity VS FCFANIP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

ANIP has a Current Ratio of 2.54. This indicates that ANIP is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of ANIP (2.54) is comparable to the rest of the industry.
A Quick Ratio of 1.96 indicates that ANIP should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.96, ANIP is in line with its industry, outperforming 45.08% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.54
Quick Ratio 1.96
ANIP Yearly Current Assets VS Current LiabilitesANIP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

8

3. Growth

3.1 Past

ANIP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 43.78%, which is quite impressive.
The Earnings Per Share has been growing slightly by 0.59% on average over the past years.
ANIP shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.50%.
The Revenue has been growing by 24.37% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)43.78%
EPS 3Y16.84%
EPS 5Y0.59%
EPS Q2Q%76.47%
Revenue 1Y (TTM)10.5%
Revenue growth 3Y41.66%
Revenue growth 5Y24.37%
Sales Q2Q%53.12%

3.2 Future

Based on estimates for the next years, ANIP will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.39% on average per year.
The Revenue is expected to grow by 11.83% on average over the next years. This is quite good.
EPS Next Y41.76%
EPS Next 2Y24.38%
EPS Next 3Y21.07%
EPS Next 5Y13.39%
Revenue Next Year40.05%
Revenue Next 2Y23.91%
Revenue Next 3Y19%
Revenue Next 5Y11.83%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ANIP Yearly Revenue VS EstimatesANIP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
ANIP Yearly EPS VS EstimatesANIP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2 4 6 8 10

More info and screens

8

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 14.24, ANIP is valued correctly.
Based on the Price/Earnings ratio, ANIP is valued cheaper than 86.53% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.08. ANIP is valued slightly cheaper when compared to this.
Based on the Price/Forward Earnings ratio of 11.45, the valuation of ANIP can be described as reasonable.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ANIP indicates a rather cheap valuation: ANIP is cheaper than 84.46% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.67. ANIP is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 14.24
Fwd PE 11.45
ANIP Price Earnings VS Forward Price EarningsANIP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ANIP is valued cheaper than 80.31% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of ANIP indicates a rather cheap valuation: ANIP is cheaper than 84.97% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 15.93
EV/EBITDA 22.23
ANIP Per share dataANIP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

ANIP's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ANIP's earnings are expected to grow with 21.07% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.34
PEG (5Y)24.25
EPS Next 2Y24.38%
EPS Next 3Y21.07%

More info and screens

0

5. Dividend

5.1 Amount

ANIP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ANI PHARMACEUTICALS INC

NASDAQ:ANIP (8/27/2025, 2:07:19 PM)

92.12

+0.23 (+0.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-08 2025-08-08/bmo
Earnings (Next)11-06 2025-11-06/bmo
Inst Owners94.91%
Inst Owner Change-1.57%
Ins Owners7.82%
Ins Owner Change-4.38%
Market Cap2.00B
Analysts84.29
Price Target97.48 (5.82%)
Short Float %12.25%
Short Ratio4.96
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.08
Dividend Growth(5Y)N/A
DP-11.43%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)22.41%
Min EPS beat(2)20.55%
Max EPS beat(2)24.28%
EPS beat(4)4
Avg EPS beat(4)19.29%
Min EPS beat(4)11.36%
Max EPS beat(4)24.28%
EPS beat(8)8
Avg EPS beat(8)20.48%
EPS beat(12)12
Avg EPS beat(12)41.58%
EPS beat(16)13
Avg EPS beat(16)15.24%
Revenue beat(2)2
Avg Revenue beat(2)7.93%
Min Revenue beat(2)6.96%
Max Revenue beat(2)8.9%
Revenue beat(4)4
Avg Revenue beat(4)5.79%
Min Revenue beat(4)0.74%
Max Revenue beat(4)8.9%
Revenue beat(8)8
Avg Revenue beat(8)7%
Revenue beat(12)12
Avg Revenue beat(12)9.13%
Revenue beat(16)15
Avg Revenue beat(16)7.25%
PT rev (1m)18.2%
PT rev (3m)17.37%
EPS NQ rev (1m)11.11%
EPS NQ rev (3m)19.28%
EPS NY rev (1m)10.8%
EPS NY rev (3m)11.94%
Revenue NQ rev (1m)7.28%
Revenue NQ rev (3m)11.29%
Revenue NY rev (1m)6.49%
Revenue NY rev (3m)7.28%
Valuation
Industry RankSector Rank
PE 14.24
Fwd PE 11.45
P/S 2.67
P/FCF 15.93
P/OCF 14.36
P/B 4.33
P/tB N/A
EV/EBITDA 22.23
EPS(TTM)6.47
EY7.02%
EPS(NY)8.04
Fwd EY8.73%
FCF(TTM)5.78
FCFY6.28%
OCF(TTM)6.41
OCFY6.96%
SpS34.46
BVpS21.28
TBVpS-5.5
PEG (NY)0.34
PEG (5Y)24.25
Profitability
Industry RankSector Rank
ROA -1.06%
ROE -3.08%
ROCE 2.06%
ROIC 1.63%
ROICexc 2.04%
ROICexgc 5.97%
OM 3.05%
PM (TTM) N/A
GM 61.06%
FCFM 16.78%
ROA(3y)-2.12%
ROA(5y)-3.36%
ROE(3y)-5.31%
ROE(5y)-7.87%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y-44.22%
ROICexc growth 3YN/A
ROICexc growth 5Y-46.62%
OM growth 3YN/A
OM growth 5Y-47.18%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.51%
GM growth 5Y-3.12%
F-Score3
Asset Turnover0.56
Health
Industry RankSector Rank
Debt/Equity 1.32
Debt/FCF 4.95
Debt/EBITDA 5.67
Cap/Depr 16.2%
Cap/Sales 1.83%
Interest Coverage 1.03
Cash Conversion 129.66%
Profit Quality N/A
Current Ratio 2.54
Quick Ratio 1.96
Altman-Z 2.22
F-Score3
WACC9.76%
ROIC/WACC0.17
Cap/Depr(3y)17.9%
Cap/Depr(5y)14.57%
Cap/Sales(3y)2.42%
Cap/Sales(5y)2.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)43.78%
EPS 3Y16.84%
EPS 5Y0.59%
EPS Q2Q%76.47%
EPS Next Y41.76%
EPS Next 2Y24.38%
EPS Next 3Y21.07%
EPS Next 5Y13.39%
Revenue 1Y (TTM)10.5%
Revenue growth 3Y41.66%
Revenue growth 5Y24.37%
Sales Q2Q%53.12%
Revenue Next Year40.05%
Revenue Next 2Y23.91%
Revenue Next 3Y19%
Revenue Next 5Y11.83%
EBIT growth 1Y-61.84%
EBIT growth 3YN/A
EBIT growth 5Y-34.31%
EBIT Next Year34.82%
EBIT Next 3Y19.79%
EBIT Next 5Y15.99%
FCF growth 1Y307.02%
FCF growth 3Y297.63%
FCF growth 5Y4.15%
OCF growth 1Y237.06%
OCF growth 3Y168.16%
OCF growth 5Y7.01%